Trially, an innovative platform that focuses on enhancing clinical trial recruitment through the power of artificial intelligence, has recently announced a significant milestone. The company has successfully secured $4.7 million in funding, which will support the launch of Margo, its new AI solution designed to enhance the recruitment process for clinical trials. The primary goal of Margo is to boost trial enrollment by effectively converting patient matches into actual participants, addressing a critical challenge in the healthcare sector.
Recruitment for clinical trials is currently one of the most urgent issues within the healthcare system. Research indicates that an alarming 86% of clinical trials face delays primarily due to difficulties in recruiting participants. As a result of these recruitment failures, the pharmaceutical industry experiences a daily loss of over $600,000. This financial setback is particularly concerning, given that patients often wait years for access to potentially life-saving treatments that could improve or extend their lives.
Trially stands out as the first fully integrated AI platform specifically designed to tackle the underlying causes of these recruitment delays. The platform utilizes HIPAA-compliant large language model agents to carefully sift through unstructured medical data. This technology allows Trially to instantly match patients with relevant clinical trials, connecting them in a way that transforms what used to require hundreds of hours of manual chart reviews and cold calling into immediate enrollment opportunities.
At the core of Trially’s offerings is Margo. This new component enhances the platform by incorporating three unique tools that work together to streamline the recruitment process. First, Trially Match analyzes comprehensive medical data to align patients with trials that are appropriate for their specific conditions. Next, the Trially Connect feature utilizes Margo’s AI to conduct outreach, pre-screen patients matched to the study, and convert those who qualify into enrolled participants. Finally, Trially Intelligence serves as a proactive monitoring tool, alerting users to trials that are a good fit for their patient population. This feature provides instant feasibility analytics, making the entire process more efficient.
The results from using Trially’s platform paint a compelling picture of its effectiveness. Organizations that have implemented this system report being able to enroll two to six times more patients each month in complex trials. The platform achieves an impressive screening accuracy of approximately 95% against eligibility criteria, resulting in a significant 73% reduction in screen failures due to better patient matching. Additionally, users of Trially’s system have found that they spend 91% less time on manual chart reviews, allowing their teams to focus on more critical tasks.
One site network even experienced a staggering $4 million increase in revenue within just three months of using Trially. In terms of efficiency, the platform identifies ten times more trial candidates instantly through its AI capabilities, underscoring the transformative potential of this technology.
The recent seed funding round for Trially was led by Flyover Capital and supported by several other investors, including Alpaca, Atria, Blu Ventures, Looking Glass Capital, Redbud, The Council, and Gaingels. This influx of capital will enable Trially to accelerate the adoption of its platform across various sectors, including research sites, pharmaceutical sponsors, contract research organizations, and physician networks.
By utilizing AI to tackle the challenges of patient enrollment, Trially and Margo represent a significant advancement in the healthcare industry, bringing hope to both researchers and patients alike.
KEY QUOTES:
“Trially’s proprietary AI has improved our ability to pre-screen candidates, reducing the time and resources typically spent on manual EHR chart reviews while improving the diversity and quality of our patient pools.”
ClinTrial Research’s Chief Commercial Officer Sam Searcy
“Patients like James Hicks shouldn’t have to wait 10 years for life-saving treatments while trials are running in their own backyard. We’re bridging the gap between life-saving medicine and the people who need it now.”
“Recruitment has always been the bottleneck in clinical research. With Margo, we’re not just matching patients, we’re engaging and enrolling them. That’s what sets Trially apart: we can identify patients with ~95% screening accuracy and then agentic AI can engage them at the exact moment it matters most.”
Kyle McAllister, Co-founder and CEO of Trially
“Clinical trial recruitment has been the industry’s Achilles’ heel for decades. Trially is the first solution we’ve seen that not only identifies eligible patients, but also engages and enrolls them. We’re thrilled to back Kyle and the Trially team as they accelerate access to life-saving treatments.”
Thad Langford, Founding Partner at Flyover Capital
